FCGR2B and melanoma: Upon investigation of the Sade-Feldman et al. dataset previously mentioned (Fig. 6k), we found that the Fgl2/FcγRIIB axis on CD8+ was clinically relevant as elevated expression of both Fcgr2b and Fgl2 on CD8+ T cells in patients with melanoma correlated with increased resistance to immune checkpoint therapy (Fig. 6l).